HUMAN PAPILLOMA VIRUS VACCINE

That this House notes the recent Department of Health decision to purchase a bivalent, rather than quadrivalent, Human Papilloma Virus (HPV) vaccine for the national HPV immunisation programme; recognises that, as well as preventing cervical cancer, a quadrivalent vaccine would protect against a wider range of conditions, including genital warts, reducing sexually-transmitted infections and costs for the NHS; understands that the UK will be the only country in the world to opt for a bivalent rather than quadrivalent vaccine for a national programme; shares the disappointment of fpa, the Terrence Higgins Trust, Brook and the British Association of Sexual Health and HIV at this decision; and urges the Government to reconsider.